Effect of KATP channel blocker glibenclamide on levcromakalim-induced headache.
Mohammad Al-Mahdi Al-KaragholiHashmat GhanizadaLili KokotiJoachim S PaulsenJakob Møller HansenMessoud AshinaPublished in: Cephalalgia : an international journal of headache (2020)
Glibenclamide administration did not cause headache, and glibenclamide pretreatment did not prevent levcromakalim-induced headache. However, glibenclamide delayed the onset of levcromakalim-induced headache. More selective blockers are needed to further elucidate the role of the ATP-sensitive potassium channel in headache initiation.Trial Registration: ClinicalTrials.gov NCT03886922.